AAPT, ZNWAL, PHOT, CHMR, AEMD, ICTY
Our Stocks to Watch today include U.S. Corp. (OTC: HAIR), All American Pet Company Inc. (OTC: AAPT), Zion Oil & Gas Inc. (Nasdaq: ZNWAL), Phototron Holdings /GrowLife Inc. (OTCBB: PHOT), Chimera Energy Corp. (OTCBB: CHMR), Aethlon Medical Inc. (OTCBB: AEMD) and Eyecity.com Inc. (OTC: ICTY).
BIOSTEM U.S. CORPORATION (OTC: HAIR)
Detailed Quote: http://www.otcpicks.com/quotes/HAIR.php
Company Profile: http://www.biostem.us
Biostem U.S., Corporation (HAIR) is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem U.S. is a technology licensing company with proprietary technology centered on providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.
August 7 - Biostem U.S., Corporation Appoints Marina Pizarro, M.D. to Scientific and Medical Board of Advisors (SAMBA)
Hair Transplant Physician Joins Prestigious Group of Physicians With Interests in the Advancement of Stem Cell Technologies in Wide Range of Disciplines
Biostem U.S., Corporation (OTC: HAIR) (“Biostem” or “the Company”), a fully reporting public company in the stem cell regenerative medicine sciences sector, announced the appointment of Marina Pizarro, M.D. to its Scientific and Medical Board of Advisors (SAMBA). Chief Executive Officer Dwight Brunoehler stated, "The addition of Dr. Pizarro to Scientific and Medical Board of Advisors rounds out our team with expertise in the field of hair re-growth using stem cells. We look forward to her interaction with the members to help advance the Company's mission to improve the quality and longevity of life for all mankind through the use of ethically sourced stem cells."
Dr. Pizarro is currently the Medical Director for Biostem U.S. as well as their trainer for the Company's hair re-growth Affiliate Program. As the company accepts qualified affiliate physicians to administer The Biostem Method™ of hair re-growth throughout the United States, Dr. Pizarro will oversee their training at her Orlando, Florida location, where she is currently accepting patients. Dr. Pizarro will begin offering the Biostem Method™ in her Tampa and Jacksonville, Florida offices in the coming months. She will also assist in overseeing the set-up of another training facility overseas as the company expands its Medical Affiliate Program internationally.
Dr. Marina Pizarro holds the distinction of being the first female hair transplant physician in the industry and belongs to the elite group of surgeons who have performed over 30,000 hair transplant procedures in their careers. She received her medical degree from Ponce School of Medicine in Puerto Rico in 1985. After completing her residency in Orlando, Dr. Pizarro worked with world renowned hair transplant surgeon Dr. Constantine Chambers building one of the largest hair restoration practices in history. After five years, and after having performed thousands of procedures around the world while lecturing at hair restoration conventions, Dr. Pizarro opened her first two facilities in Orlando and Jacksonville, Florida in 1994, specializing in hair transplantation for both men and women. She currently has three facilities in Florida with the addition of her clinic in Tampa. Dr. Pizarro is a member of The International Society of Hair Restoration Surgery and the European Society of Hair Restoration Surgery.
ALL AMERICAN PET COMPANY (OTC: AAPT)
"Up 55.04% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/AAPT.php
All American Pet Company produces, markets, and sells natural super-premium and premium patented wellness products under proprietary brand names specifically for dogs. Forward-looking Statements: This release contains statements that are forward-looking in nature — statements that are predictive and which depend upon or refer to future events or conditions. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to, dependence on suppliers; lack of financing; delays in development or shipment of new products; introduction of new products by major competitors; inability to expand our operations to support increased growth; and declining economic conditions.
August 9 - All American Pet Company, Inc. Gets Vendor Approval From the World's Largest Drugstore Chain With Commitments to Merchandise the First of Its Kind Line of NutraBars™ for Dogs
All American Pet Company, Inc. (OTC: AAPT) VP of national sales, Jim Colyer, presented the company's newest innovation yesterday and came back with vendor approval from the largest drugstore chain in the world with assurances for orders to fill over 7900+ stores with three SKU's of NutraBars™ — the first-ever all natural super premium hi-pro-power bar for dogs based on the buyer's reception.
With the price of gas soaring, dog owners are buying more dog food and snacks from their neighborhood drug stores. According to Symphony IRI data dog food sales soared 17% in the drug channel vs. a decline of 0.04% at supermarkets — it's just more convenient and shoppers are not committed to filling their carts to feed the family's Fido.
"Our operations team has booked production time in Kansas. We've got full production runs scheduled for the 14th and 15th and will have over 300,000 of the 4oz bars: Original, Low Fat and Senior Formulas ready to ship. Dates for making millions more are scheduled throughout September to meet Q4 commitments. The market is really hungry for NutraBar and that is why AAPT retained Susan Hartzler's specialty AlphadogPR firm to whet everyone's appetite for more," said Lisa Bershan, President AAPT.
The $5B bar business for people is bulging with competitors, but only AAPT is making nutritional bars for the nation's 78.5 million dogs. NutraBar is the only heart-healthy, 25% protein bar made in the USA that meets all of the AAFCO requirements for a real food, but available for the first time in a convenient, affordable and safe bar — just like human bar brands.
Barry Schwartz, CEO AAPT revealed, "We've got 16 of the top sales pros in the business. When we send the team out into the marketplace they come back with a resounding: 'When can we get them' buyer response." Schwartz continued, "We are current with our production projections and marketing plans and on track with our financial filings and distribution to be in at least 50,000 retail doors by year's end. We've got our teeth into the bar business and we are not letting go."
ZION OIL & GAS INCORPORATED (NASDAQ: ZNWAL)
"Up 33.33% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ZNWAL.php
Zion Oil & Gas, a Delaware corporation, explores for oil and gas in Israel in areas located onshore between Haifa and Tel Aviv. It currently holds three petroleum exploration licenses: the Joseph License (on approximately 83,272 acres) and the Asher-Menashe License (on approximately 78,824 acres) between Netanya, in the south, and Haifa, in the north, and the Jordan Valley License (on approximately 55,845 acres), just south of the Sea of Galilee. The total license area amounts to approximately 218,000 acres.
August 2 - Zion Oil Confirms Three Day Broker Protect Period for ZNWAL Warrants
Zion Oil & Gas, Inc. (Nasdaq: ZNWAL) confirmed that its common stock warrants which publicly trade under the symbol "ZNWAL" on the NASDAQ Global Market will expire and cease to trade at 5:00 PM Eastern Daylight Time on August 15, 2012.
Zion will extend a three trading day broker protect period for any trades of the ZNWAL warrants that occur through the scheduled expiration date. Holders wishing to exercise the ZNWAL warrants must deliver funds for the exercise by 5:00 PM Eastern Daylight Time on August 15, 2012, the scheduled expiration date, and the warrant holders' brokers have until 5:00 PM Eastern Daylight Time on August 20, 2012 to complete the transaction with Zion's transfer agent, Registrar and Transfer Company (RTC). The exercise price of the ZNWAL warrants is $1.75 per share.
In order to exercise a warrant, the warrant holder may contact his or her broker, who will be able to electronically exercise the warrant through a system operated by The Depository Trust & Clearing Corporation (DTCC). Brokers are encouraged to contact the Company's transfer agent, RTC by telephoning 1-800-368-5948, in advance of the expiration date to confirm the procedures for exercising warrants and payment of exercise prices in light of the broker protect period.
PHOTOTRON HOLDINGS INCORPORATED (OTCBB: PHOT)
"Up 52.31% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/PHOT.php
Phototron Holdings, Inc. is a progressive company with core holdings in innovative technology-based products and services for home gardening specialty markets including Stealth Grow LED brand LED grow lights and the Phototron single plant systems and accessories.
August 6 - Phototron Holdings Announces Name Change to GrowLife and Outlines Recent Accomplishments
Phototron Holdings, Inc., a leading hydroponics and lifestyle company, announced that effective August 6, 2012, it has changed its name to GrowLife, Inc. GrowLife, Inc. will continue to be traded on the public markets without disruption under the same trading ticker symbol “PHOT,” with the new slogan “Grow to Live, Live to Grow.”
“Our active leadership in the ‘Grow to Live, Live to Grow’ movement is best achieved under the GrowLife, Inc. brand of products.”
GrowLife, Inc. CEO, Sterling Scott, commented, “We have broadened the mission, goals and the assets of the company quite substantially over the last four months. We believe that GrowLife, Inc. as the name of our company resonates and describes our mission more effectively than Phototron Holdings. Going forward, we remain very committed to Phototron products, as one of many highly valued brands within our company.”
Over the past few months, the company has accomplished the following:
* GrowLife now owns and markets www.Greners.com, the leading online hydroponics supply company in North America;
* GrowLife now owns and operates www.stealthgrow.com, the leading manufacturer and supplier of LED grow lights in our business;
* GrowLife is beta testing a complete line of grow room automation equipment under our SG Sensors brand for launch later this year;
* GrowLife established GrowLife Productions, Inc. as an operating division of our company that is focused on brand promotion opportunities in the entertainment and lifestyle market surrounding the medicinal cannabis industry; and
* GrowLife has strengthened our management team and Board of Directors and initiated the development of a strategic Advisory Board for the Company.
“We have the unique opportunity to become the dominant and most important company in our specialty industry, and an even broader opportunity to participate in the sustainable food industry,” added Mr. Scott. “Our active leadership in the ‘Grow to Live, Live to Grow’ movement is best achieved under the GrowLife, Inc. brand of products.”
CHIMERA ENERGY CORPORATION (OTCBB: CHMR)
"Up 30.61% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/CHMR.php
Chimera Energy Corp is a Texas corporation listed on the OTCBB under the trading symbol CHMR. Chimera Energy Corp (CHMR) acquires, develops, licenses and sells new energy technology and products that are designed to profit from the current domestic shale oil boom. CHMR competes in an industry sector that includes Halliburton (HAL), Schlumberger (SLB), EnCana Corporation (ECA) and Continental Resources, Inc. (CLR).
August 9 - PEMEX Signs Deal with CHMR for New Non-Hydraulic Shale Oil Extraction System Designed to Safely Replace Hydraulic Fracturing
Chimera Energy Corp. (OTCBB: CHMR) announced that they have executed a Memorandum of Understanding with PEMEX, also known as Petroleos Mexicanos, regarding the utilization of CHMR’s revolutionary exothermic Non-Hydraulic Extraction method throughout Latin America. The Non-Hydraulic Extraction method is a revolutionary Shale Oil extraction technology designed to safely and economically replace hydraulic fracturing (AKA fracking and fracing) without negative environmental impacts. The new process uses no water.
PEMEX is the largest company in both Mexico and all of Latin America. Some of the largest concentrations of Shale Oil in the world are located throughout Latin America. The MOU precedes a supplemental encompassing agreement.
Non-Hydraulic Extraction has recently emerged to be asserted as a cheaper and more effective extraction method that does not affect groundwater at all. Chimera Energy Corp is in the process of reengineering this new method for mass production, relicensing and sales.
AETHLON MEDICAL INCORPORATED (OTCBB: AEMD)
"Up 26.74% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/AEMD.php
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with DARPA that would reduce the incidence of sepsis in combat-injured soldiers and civilians.
August 9 - Aethlon Medical Announces Expanded Access to Hemopurifier® Therapy For Individuals Infected with Hepatitis C Virus (HCV)
Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has agreed to establish a treatment program that will provide HCV-infected individuals with expanded access to Hemopurifier® therapy. The program is being initiated with support from the Institutional Review Board at the Medanta Medicity Institute (Medicity) to allow compassionate usage of the Aethlon Hemopurifier® for individuals who previously failed or subsequently relapsed standard-of-care drug regimens.
In addition to offering Hemopurifier® therapy to the citizens of India, HCV-infected individuals from the United States, European Union and other regions of the world may pursue treatment through the expanded access program. Details related to treatment protocol, inclusion criteria, patient approval processes and therapy pricing are anticipated in September. It is estimated that approximately 170 million people worldwide are infected with HCV, which leads to chronic liver disease or cirrhosis, and is a leading cause of liver transplantation.
The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of HCV from the entire circulatory system to improve benefit, dose, duration and tolerability of drug therapies. The Medicity is a $360 million multi-specialty medical institute established to be a premier center for medical tourism in India.
"The Medicity access program represents an important milestone in our quest to establish the selective therapeutic filtration industry," stated Aethlon Chairman and CEO, Jim Joyce. "Beyond helping HCV-infected individuals overcome their disease, we now have the opportunity to augment our established government contract revenues with Hemopurifier® product sales."
Aethlon also disclosed that it will continue conducting a study at the Medicity that is evaluating the capability of the Aethlon Hemopurifier® to accelerate HCV RNA depletion at the outset of standard of care peginterferon+ribavirin (PR) therapy. Specifically, HCV-infected individuals are enrolled to receive up to three, six-hour Hemopurifier® treatments during the first three days of PR drug therapy. Last week, Aethlon reported that the two most recent HCV infected patients to receive Hemopurifier® therapy in combination with PR drug therapy achieved undetectable viral load at day-7, which is rarely reported in drug therapy alone.
The primary clinical endpoint of the Medicity protocol has been to increase the incidence of rapid virologic response (RVR), defined as undetectable HCV RNA at day 30 of therapy. RVR represents the clinical endpoint that best predicts treatment cure, otherwise known as sustained virologic response (SVR), defined as undetectable HCV RNA 24-weeks after the completion of PR drug therapy. As a point of reference, the landmark IDEAL Study of 3,070 HCV genotype-1 patients documented that only 10.35% (n=318/3070) of PR treated patients achieved a RVR. However, patients that achieved a RVR had SVR rates of 86.2% (n=274/318) versus SVR rates of 32.5% (n=897/2752) in non-RVR patients. While the incidence of undetectable HCV RNA at day-7 is not reported in the IDEAL study, the study did reveal that just 4.3% (n=131/3070) of patients achieved undetectable HCV RNA at day-14, which equated to a 91% (n=118/131) SVR rate.
Aethlon reported that Hemopurifier® therapy has been well tolerated and without device-related adverse events in ten treated patients. Of these ten patients, seven patients were infected with HCV genotype-1; two patients were infected with HCV genotype-3; and one patient was infected with HCV genotype-5. At present, undetectable HCV RNA is reported in eight of the 10 treated patients. Of the two patients with detectable HCV RNA, one discontinued PR therapy as a result of a diabetes related condition. HCV RNA is undetectable in all patients (n=4) that have been monitored for 48 weeks since receiving Hemopurifier® therapy. Among the 10 treated patients, Aethlon reported that six genotype-1 patients received the three treatment Hemopurifier® protocol, which resulted in four (67%) patients achieving a RVR. The IDEAL study predicts it would normally require approximately 40 PR treated patients to achieve 4 RVR outcomes. Both patients who achieved undetectable HCV RNA at day-7 also achieved a RVR. Beyond the high likelihood of a SVR, genotype-1 patients that achieve a RVR also have the opportunity to reduce the duration of PR drug therapy from 48 weeks to 24 weeks.
In addition to expanding access to Hemopurifier® therapy at the Medicity, Aethlon is preparing to resubmit to the FDA an investigational device exemption (IDE), which will incorporate the Medicity data in an effort to gain approval to initiate HCV clinical programs in the United States.
EYECITY.COM INCORPORATED (OTC: ICTY)
"Up 50.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ICTY.php
EyeCity.com Inc., headquartered in Dallas, TX, is a publicly traded corporation designed to be a life style company orchestrated for the middle class with a millionaire attitude. The Vande Flash clothing brand will be a trend setter in style while bringing a variety of influences to the public market. While manufacturing some of the most sought after clothing and opening retail boutiques around the country, Vande Flash will engage in bringing other business models into a company that only the affluent life style demands.
No recent news for Eyecity.com, Inc. (OTC: ICTY).